Y-mAbs Therapeutics Surpasses Expectations with Increased Revenue and Earnings

Trending News ☀️

Y-MABS ($NASDAQ:YMAB): Y-mAbs Therapeutics, a biopharmaceutical company focused on making novel therapies for cancer, has surpassed expectations with their financial results. The company reported its GAAP EPS of -$0.15, exceeding analyst estimates by $0.17, while their revenue of $20.25M exceeded analyst estimates by $4.7M. This impressive performance was driven by the company’s continued growth in its product sales and their strategic partnerships. The company’s success is due in part to Y-mAbs’ commitment to developing innovative therapies to fight cancer.

Y-mAbs also recently announced a partnership with Merck, which will help bring their products to more patients in the near future. Overall, Y-mAbs Therapeutics has demonstrated impressive growth and profitability in the past few quarters. With their continued commitment to innovation and strategic partnerships, the company is well-positioned to continue this success in the future.

Earnings

Y-MABS THERAPEUTICS recently released its earning report for Q4 of the fiscal year 2022 ending December 31, 2022, showcasing significant growth in revenue and earnings. The report showed that Y-MABS THERAPEUTICS earned a total revenue of 31.45M USD, up 227.6% from the previous year, and net income of 1.16M USD, down 103.1% from the prior year. This marks a dramatic increase in total revenue for Y-MABS THERAPEUTICS, which has grown from 20.75M USD to 31.45M USD in the last 3 years. These results demonstrate that Y-MABS THERAPEUTICS has exceeded expectations and is continuing to expand its operations.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Y-mabs Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Y-mabs Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Y-mabs Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Y-mabs Therapeutics are shown below. More…

Share Price

Y-mAbs Therapeutics made a positive impression on Monday, as the company surpassed expectations for revenue and earnings. The stock opened at $6.9 and closed at $6.8, down by 2.0% from the previous closing price of $6.9. Despite the negative change in stock price, the company significantly exceeded expectations in terms of both revenue and earnings for the quarter. Y-mAbs Therapeutics has recently been focusing on developing an array of innovative treatments and therapies for cancer, including antibody-drug conjugates and small molecule drugs.

The company has made strides in its ability to provide affordable, effective treatments to patients all around the world, further enhancing its reputation among medical professionals and investors alike. The release of these increased revenue and earnings numbers is a clear indication that Y-mAbs Therapeutics is headed in the right direction and is likely to gain even more success in the near future. As the company continues to research and develop innovative treatments, investors can expect to see an increase in share prices as more people become aware of the tremendous potential held by Y-mAbs Therapeutics. Live Quote…

Analysis

GoodWhale has conducted an analysis of Y-MABS THERAPEUTICS‘s financials and classified it as a ‘cheetah’ company based on our Star Chart. This type of company typically achieves high revenue or earnings growth, but is considered less stable due to lower profitability. This combination of factors may make the company attractive to investors who seek short-term returns on their investments. Y-MABS THERAPEUTICS also has an intermediate health score of 4/10 with regard to its cashflows and debt, indicating that the company might be able to safely ride out any crisis without the risk of bankruptcy. Our analysis also found that Y-MABS THERAPEUTICS is strong in asset growth, while it is weaker in dividend and profitability metrics. More…

Peers

The company’s lead product candidate, naxitamab, is in clinical development for the treatment of neuroblastoma, a rare and aggressive pediatric cancer. Y-mAbs Therapeutics Inc’s other product candidates are in clinical and preclinical development for the treatment of solid tumors and blood cancers. The company’s competitors include BioAtla Inc, Adagio Therapeutics Inc, and Orphazyme AS.

– BioAtla Inc ($NASDAQ:BCAB)

BioAtla Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of immuno-oncology agents. The company’s market cap as of 2022 is 357.65M and its ROE is -41.59%. BioAtla’s main competitors are Bluebird bio, Inc. (NASDAQ: BLUE) and Celgene Corporation (NASDAQ: CELG).

– Adagio Therapeutics Inc ($NASDAQ:ADGI)

Orphazyme AS is a biotech company that focuses on developing treatments for rare diseases. The company has a market cap of 5.88M as of 2022 and a Return on Equity of -845.21%. Despite its negative ROE, Orphazyme AS’s market cap indicates that investors are confident in the company’s future prospects. This is likely due to the fact that Orphazyme AS is working on developing treatments for rare diseases, which is a highly lucrative market.

Summary

The company reported a GAAP EPS of -$0.15, which beat analyst estimates by $0.17. Furthermore, revenues of $20.25M beat estimates by $4.7M. Analysts believe that the company’s strong performance reflects the progress being made in its pipeline and its focus on high-value treatments for cancer and autoimmune disorders.

Investors should focus on Y-MABS’s ability to bring new treatments to market and its strategic actions to bring promising treatments to patients. The company’s strong fundamentals and encouraging outlook make it a compelling investment option in the healthcare sector.